ѻý

NeuroBreak: DEA Opioid Case Ends with Whimper; Acthar's High Prescribers

<ѻý class="mpt-content-deck">— News and commentary from the world of neurology and neuroscience
MedpageToday

DEA investigators worked for 6 years to build a case against Mallinckrodt for its role in the opioid epidemic, particularly in Florida, but the government has . Instead, a $35-million settlement with no admission of wrongdoing may be the likely outcome. (Washington Post)

Why are some doctors , when there's no proof it works better than cheap generic steroids? (Business Insider)

The FDA has okayed Teva's . This is a first approval for any deuterated drug, which enables a slowed breakdown of the active molecule for better dosing. Deutetrabenazine is a small molecule inhibitor of the vesicular monoamine 2 transporter (VMAT2), which regulates dopamine levels in the brain. (Endpoints News)

The agency also green-lighted for treating opioid-induced constipation in adults with non-cancer chronic pain. And it expanded the indication of extended-release topiramate (Qudexy) to include in adults and adolescents.

Higher C-reactive protein levels may for patients with ALS, according to a retrospective analysis of data from three trials. (JAMA Neurology)

ACP: Treat addiction and substance use disorders as you would other chronic conditions. (ѻý)

Can the diuretic agent bumetanide ? (Spectrum)

A federal judge , opening the door to generic versions of the MS drug. (Reuters)